Amgen Inc. announced today a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs. The investment will support increased drug production at the company’s biologics manufacturing facility in Juncos, Puerto Rico, and integrate advanced technologies throughout the operations process.
The expansion is expected to create nearly 750 jobs, including construction roles and highly skilled manufacturing positions. By bolstering domestic production capacity, Amgen aims to strengthen supply‑chain resilience amid potential tariff threats and regulatory changes.
The move aligns with Amgen’s broader strategy to reduce reliance on overseas manufacturing, enhance operational efficiency, and support the growth of its biologics pipeline. The investment is a tangible step toward sustaining long‑term growth and maintaining competitive advantage in the biopharmaceutical market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.